Compare NetApp Inc. (NTAP) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Natera Inc. Common Stock — how do they compare? NetApp Inc. trades at $216.73 (market cap $46.95B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and NetApp Inc. pays a 0.87% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Natera Inc. Common Stock for 0 Days on average.
| NTAP | NTRA | |
|---|---|---|
Market Cap | $46.95B | $57.03B |
Volume | 2,358,705 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $239.23 | $425.64 |
52-Week Low | $94.11 | $179.42 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $45.90B | $56.18B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $222.2, down 7.12% over the past day, yet maintains a strong fundamental profile with robust profitability margins and consistent earnings beats. The stock exhibits a bullish technical signal, supported by moving averages, though oscillators indicate potential overbought conditions. Recent strategic announcements at INSIGHT 2026, including AI infrastructure partnerships and new product launches, highlight the company's focus on capitalizing on data and AI-driven demand.
The outlook for NTAP is positive, driven by solid earnings growth, strategic AI initiatives, and favorable analyst sentiment, but risks include high valuation multiples, competitive pressures in the storage sector, and macroeconomic sensitivity. The consensus price target of $219.30 suggests limited near-term upside from current levels, warranting caution amid recent volatility.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
